TIGIT is an inhibitory receptor expressed on T cells and natural killer cells and regulates anti-tumor immunity through competition with CD226 for binding to CD155, and increased expression of TIGIT in bladder tumors is associated with impaired effector function. Here, CD226 is linked to neoplasm.